VALUE is the Trending Word of 2023
BioSpectrum Asia|BioSpectrum Asia Feb 2023
The last two years saw a significant leap toward patient-centricity in the pharmaceutical space. although this next iteration will focus on leveraging the industry's growing digital maturity to offer increased patient value while achieving measurable business goals.
VALUE is the Trending Word of 2023

This shift will be driven by a host of factors. As we enter the digital age, most people-including patients, caregivers, physicians and other healthcare professionals-expect more from the brands they interact with. Gone are the days when a basic pharmaceutical website or simple app was enough to impress these external stakeholders-today, they want to see more advanced and useful user experiences.

At the same time, the concept of value-based pricing has started to percolate in recent years. Essentially, a growing number of payers are challenging the traditional pricing structure of many pharmaceutical drugs and looking for proof that they warrant their associated price tag. Pharmaceutical companies, therefore, will be under increased pressure in 2023 to demonstrate that their products provide real value.

These forces, and others, are inspiring many companies to rethink their traditional business model and unlock new opportunities to provide patient value. In 2023, this will likely culminate in more value-based marketing strategies designed to forge a genuine connection with patients. Companies will uncover ways to bring new drugs to market faster and more cost effectively and use the vast amount of data at their disposal to guide product decisions in a more tactical, and deliberate, manner. They may even strive to expand their offerings in the name of value - finding new ways to utilise technology, or content, to enhance the patient experience.

To help envision what this may look like, below are four trends we expect to arise in the pharmaceutical space in 2023.

1. Data-informed decision making 

Diese Geschichte stammt aus der BioSpectrum Asia Feb 2023-Ausgabe von BioSpectrum Asia.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der BioSpectrum Asia Feb 2023-Ausgabe von BioSpectrum Asia.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS BIOSPECTRUM ASIAAlle anzeigen
Prof. Christian Wolfrum to join NTU as Deputy President and Provost
BioSpectrum Asia

Prof. Christian Wolfrum to join NTU as Deputy President and Provost

Nanyang Technological University, Singapore (NTU Singapore) has announced that Professor Christian Wolfrum, an eminent biomedical scientist, will be joining the University as the next Deputy President and Provost.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Japan suggests addition of PVA into drugs for strong antitumour activity
BioSpectrum Asia

Japan suggests addition of PVA into drugs for strong antitumour activity

Treatment for more advanced and difficult-to-treat head and neck cancers can be improved with the addition of polyvinyl alcohol (PVA), the same ingredient used in children's glue.

time-read
1 min  |
BioSpectrum Asia Feb 2025
"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"
BioSpectrum Asia

"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"

2024 saw Japanese medtech firm Olympus receiving approval for the company's first cloud-based AI endoscopy devices in the US and Europe, marking a significant milestone in Olympus' efforts to enhance clinical outcomes and operational efficiency in endoscopy, paving the way to launch its upcoming endoscopy solution, the “Intelligent Endoscopy Ecosystem”.

time-read
5 Minuten  |
BioSpectrum Asia Feb 2025
BeiGene names Giancarlo Benelli as Head of Europe biz
BioSpectrum Asia

BeiGene names Giancarlo Benelli as Head of Europe biz

BeiGene, a Hong Kong-headquartered oncology company that intends to change its name to BeOne Medicines Ltd., has announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Korea develops innovative injectable adhesive hydrogel for bone regeneration
BioSpectrum Asia

Korea develops innovative injectable adhesive hydrogel for bone regeneration

A research team from South Korea-based Pohang University of Science and Technology or POSTECH's Department of Chemical Engineering and Graduate School of Convergence Science and Technology, along with the Department of Chemical Engineering, has developed an innovative injectable adhesive hydrogel for bone regeneration.

time-read
1 min  |
BioSpectrum Asia Feb 2025
When Clinical Trials Suffer From 'Complicated' Interactions
BioSpectrum Asia

When Clinical Trials Suffer From 'Complicated' Interactions

Diversity in culture, language, and data gathering methods will further increase the difficulty of clinical trials as they become more international, particularly with the growing number of sites being employed across China, Japan, South Korea, and India.

time-read
5 Minuten  |
BioSpectrum Asia Feb 2025
Dr Krishna M Ella receives prestigious INSA India fellowship
BioSpectrum Asia

Dr Krishna M Ella receives prestigious INSA India fellowship

Dr Krishna Ella, a distinguished scientist, co-founder and Executive Chairman of Bharat Biotech International, has been recognised with the prestigious India Fellowship of the Indian National Science Academy (INSA) for the year 2025, for his contributions to new knowledge, discoveries, development of new vaccine technologies, noteworthy improvement in existing technologies.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Bruker launches infrared imaging microscope for pharma and life science research
BioSpectrum Asia

Bruker launches infrared imaging microscope for pharma and life science research

US-based Bruker Corporation has announced the launch of the LUMOS II ILIM, a quantum cascade laser (QCL) based infrared (IR) imaging microscope.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities
BioSpectrum Asia

Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities

Qiagen has announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analysed from a single biological sample.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers
BioSpectrum Asia

Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers

US-based Repligen Corporation has announced the commercial launch of its CTech SoloVPE PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers.

time-read
1 min  |
BioSpectrum Asia Feb 2025